Lonza Group AG (LZAGY)
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Sector: Biotechnology
Industry: Biotechnology
Lonza Group AG
- 0.1%
- 57.0K
- 1.00
Float 69.81M · FMP free float
The cost to borrow LZAGY shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 27.2%
- 37
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 57.0K sh |
| Oct 15, 2026 | 35.7K sh |
| Sep 30, 2026 | 35.3K sh |
| Sep 15, 2026 | 27.9K sh |
| Aug 31, 2026 | 77.7K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 27, 2026 | 37 sh |
| Oct 26, 2026 | 2.2K sh |
| Oct 20, 2026 | 207 sh |
| Oct 13, 2026 | 1.3K sh |
| Oct 9, 2026 | 2.5K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 27.2% |
| Nov 13, 2026 | 44.8% |
| Nov 12, 2026 | 68.5% |
| Nov 11, 2026 | 51.5% |
| Nov 10, 2026 | 42.7% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for LZAGY: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 57,025 LZAGY shares were sold short (0.08% of a 69.81M-share float, 1.00 days to cover).